MA38207A2 - Quinolyl-hydrazones pour le traitement de la tuberculose et de maladies associées - Google Patents

Quinolyl-hydrazones pour le traitement de la tuberculose et de maladies associées

Info

Publication number
MA38207A2
MA38207A2 MA38207A MA38207A MA38207A2 MA 38207 A2 MA38207 A2 MA 38207A2 MA 38207 A MA38207 A MA 38207A MA 38207 A MA38207 A MA 38207A MA 38207 A2 MA38207 A2 MA 38207A2
Authority
MA
Morocco
Prior art keywords
hydrazones
quinolyl
tuberculosis
related diseases
treatment
Prior art date
Application number
MA38207A
Other languages
English (en)
Other versions
MA38207B1 (fr
Inventor
Ferreira Ana Lúcia Almeida
Ana Sofia Lopes
Filipe Augusto Eugénio Pardal
Carlos Caixado
Pedroso Pedro Filipe Eufrásio
Almeida Pecorelli Susana Marques De
Original Assignee
Tecnimede Soc Tecnico-Medicinal S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Soc Tecnico-Medicinal S A filed Critical Tecnimede Soc Tecnico-Medicinal S A
Publication of MA38207A2 publication Critical patent/MA38207A2/fr
Publication of MA38207B1 publication Critical patent/MA38207B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des quinolyl-hydrazones de formule (i), ou des sels, esters, solvates, isomères et promédicaments pharmaceutiquement acceptables de ceux-ci, ainsi que des compositions pharmaceutiques contenant ces composés, à utiliser pour le traitement prophylactique et/ou thérapeutique de la tuberculose et de maladies associées, par exemple, des maladies causées par des mycobactéries non tuberculeuses et/ou par
MA38207A 2012-11-20 2013-11-20 Quinolyl-hydrazones pour le traitement de la tuberculose et de maladies associées MA38207B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PT106651A PT106651A (pt) 2012-11-20 2012-11-20 Quinolil hidrazonas para o tratamento de tuberculose e doenças relacionadas
PCT/PT2013/000069 WO2014081325A1 (fr) 2012-11-20 2013-11-20 Quinolyl-hydrazones pour le traitement de la tuberculose et de maladies associées

Publications (2)

Publication Number Publication Date
MA38207A2 true MA38207A2 (fr) 2016-12-30
MA38207B1 MA38207B1 (fr) 2018-06-29

Family

ID=49876953

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38207A MA38207B1 (fr) 2012-11-20 2013-11-20 Quinolyl-hydrazones pour le traitement de la tuberculose et de maladies associées

Country Status (17)

Country Link
US (1) US9809550B2 (fr)
EP (1) EP2934528B1 (fr)
BR (1) BR112015011605A2 (fr)
CY (1) CY1121690T1 (fr)
DK (1) DK2934528T3 (fr)
ES (1) ES2710124T3 (fr)
HR (1) HRP20182198T1 (fr)
HU (1) HUE043021T2 (fr)
LT (1) LT2934528T (fr)
MA (1) MA38207B1 (fr)
PL (1) PL2934528T3 (fr)
PT (2) PT106651A (fr)
RS (1) RS58185B1 (fr)
SI (1) SI2934528T1 (fr)
SM (1) SMT201900089T1 (fr)
TR (1) TR201900156T4 (fr)
WO (1) WO2014081325A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4422616A4 (fr) * 2021-10-26 2025-08-13 Spero Therapeutics Inc Dose efficace humaine et programme de dosage de spr720

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080118576A1 (en) * 2006-08-28 2008-05-22 Dan Theodorescu Prediction of an agent's or agents' activity across different cells and tissue types
CN102224151A (zh) * 2008-11-20 2011-10-19 万能药生物有限公司 新的抗微生物剂
EP2287149A1 (fr) * 2009-08-20 2011-02-23 Max-Delbrück-Centrum Für Molekulare Medizin Activateurs de dégradation de protéine
EP2311457A1 (fr) 2009-10-19 2011-04-20 Forschungszentrum Borstel Compositions pharmaceutiques pour traiter les infections avec des mycobactéries résistantes aux médicaments
ES2532703T3 (es) * 2010-10-13 2015-03-31 Glaxo Group Limited Derivados de 3-amino-pirazol útiles contra la tuberculosis

Also Published As

Publication number Publication date
DK2934528T3 (en) 2019-02-04
PL2934528T3 (pl) 2019-05-31
PT106651A (pt) 2014-05-20
SMT201900089T1 (it) 2019-02-28
CY1121690T1 (el) 2020-07-31
ES2710124T3 (es) 2019-04-23
RS58185B1 (sr) 2019-03-29
LT2934528T (lt) 2019-02-11
EP2934528B1 (fr) 2018-11-07
MA38207B1 (fr) 2018-06-29
US9809550B2 (en) 2017-11-07
US20150299128A1 (en) 2015-10-22
PT2934528T (pt) 2019-03-20
WO2014081325A1 (fr) 2014-05-30
HRP20182198T1 (hr) 2019-02-22
TR201900156T4 (tr) 2019-02-21
EP2934528A1 (fr) 2015-10-28
BR112015011605A2 (pt) 2017-07-11
SI2934528T1 (sl) 2019-03-29
HUE043021T2 (hu) 2019-08-28

Similar Documents

Publication Publication Date Title
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA38398B1 (fr) Composés biaryle amides en tant qu'inhibiteurs de kinase
CA2878796C (fr) Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA35576B1 (fr) Nouveaux composés
MA37886A1 (fr) Nouvelles pyridinones bicycliques
MA38810A1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA35285B1 (fr) Indazoles
MA35184B1 (fr) Antagonistes de trpv4
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA35638B1 (fr) 2-thiopyrimidinones
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
EA201991916A1 (ru) 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA39750B1 (fr) Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
MA38207B1 (fr) Quinolyl-hydrazones pour le traitement de la tuberculose et de maladies associées
MA38206A1 (fr) Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées